A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01683279
Recruitment Status : Active, not recruiting
First Posted : September 11, 2012
Last Update Posted : March 8, 2018
Information provided by (Responsible Party):
Rebecca Gardner, Seattle Children's Hospital

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : January 2031
  Estimated Study Completion Date : January 2031